SCHEMBL23748168

SCHEMBL23748168

C=CCc1ccccc1C(O)c1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
ADRA2C P18825 3/20 0.40
ADRA2A P08913 2/20 0.40
ADRA2B P18089 2/20 0.40
ALDH1A1 P00352 2/20 0.38
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
ADRB2 P07550 3/20 0.36
ADRB1 P08588 3/20 0.36
LMNA P02545 2/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
TSHR P16473 2/20 0.36
HTR1A P08908 2/20 0.36
ADRB3 P13945 1/20 0.36
BDKRB2 P30411 1/20 0.36
ADRA1A P35348 1/20 0.36
HTR2B P41595 1/20 0.36
KCNH2 Q12809 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748161 0.85 MAPT (0.43) MAPTADRA2AALDH1A1LMNASLC6A2
SCHEMBL23748215 0.82 ADRA2B (0.40) MAPTADRA2CADRA2AADRA2BALDH1A1
SCHEMBL23748213 0.77 LIG1 (0.43) MAPTALDH1A1ADRB2ADRB1LMNA
SCHEMBL24353892 0.76 GABRA1 (0.42) MAPTADRA2CADRA2AADRA2BALDH1A1
SCHEMBL23748219 0.73 F2RL1 (0.43) MAPTALDH1A1LMNAKCNH2KDM4E
SCHEMBL6269535 0.73 GABRA1 (0.46) ADRA2CADRA2AADRA2BALDH1A1GABRA1
SCHEMBL29864658 0.72 MAPT (0.55) MAPTALDH1A1LMNASLC6A2SLC6A4
SCHEMBL3048607 0.72 MAPT (0.55) MAPTALDH1A1LMNASLC6A2SLC6A4
SCHEMBL18496129 0.72 MAPT (0.53) MAPTGABRA1GABRB2LMNASLC6A2
SCHEMBL29618691 0.72 MAPT (0.53) MAPTGABRA1GABRB2LMNASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 MAPT 2999/4885ADRA2C 3074/4885ADRA2A 3903/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP MAPT 3026/4885ADRA2C 2994/4885ADRA2A 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.